首页 AbbVie(usABBV)-基本信息

AbbVie(usABBV)-基本信息

日报更新时间:04-10 10:00

周报更新时间:04-11 03:39

行情信息

今开价:107.82

最高价:108.57

成交量:5642672.0

昨收价:107.54

最低价:107.36

最新价:108.25

行情图标
概要信息

英文名称:AbbVie


简介:艾伯维公司注册成立于2012年4月10日,是一家全球性的、以研究为基础的生物制药公司


电话:1-847-9327900


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

2011年10月19日,雅培实验室(Abbott Laboratories)宣布计划分拆为两家上市公司。“新”雅培实验室将专注于多种产品,包括医疗设备,诊断设备和营养产品,而AbbVie将作为研究型制药企业运营。该分离于2013年1月1日生效,AbbVie于2013年1月2日在纽约证券交易所(ABBV)正式上市。根据当时首席执行官迈尔斯怀特(Miles White)的说法,分拆的目的是让市场分别对这两家公司进行估值; 怀特表示,投资者将“从两个根本不同的投资机会中受益,具有独特的战略形象和业务重点。” 一些投资者担心这样做是为了保护设备业务的价值,使其免受药品部门面临的价值损失的影响,因为Humira的专利即将到期,后者约占药品部门收入的一半。艾伯维公司在世界范围内从事发现、开发、制造和销售各类医药产品。公司产品包括: HUMIRA - 一种生物疗法,用于皮下注射治疗自身免疫性疾病和肠道Behçet病 IMBRUVICA - 治疗成人慢性淋巴细胞白血病(CLL),小淋巴细胞淋巴瘤(SLL),套细胞淋巴瘤,waldenström巨球蛋白血症,边缘区淋巴瘤和慢性移植物抗宿主病 VENCLEXTA,一种BCL-2抑制剂,用于治疗成人CLL或SLL VIEKIRA PAK - 一种纯口服、短程、无干扰素疗法,用于治疗成年患者基因1型慢性肝炎(HCV),包括代偿性肝硬化 TECHNIVIE - 治疗基因4型HCV感染的成人 MAVYRET - 治疗慢性HCV基因1-6型感染的患者 Kaletra - 一种抗HIV-1药物,用于抑制HIV-1病毒在人体内的复制、扩散(抗艾滋药);与其他抗HIV-1药物一起用于维持HIV-1患者的病毒抑制 Norvir - 一种蛋白酶抑制剂,与其他抗逆转录病毒药物联合使用治疗HIV-1感染(抗艾滋药) Synagis - 预防婴儿呼吸道合胞病毒感染 AndroGel - 睾酮替代疗法,用于治疗男性睾丸激素水平低症状 Creon - 胰腺酶疗法,用于外分泌胰腺功能不全 Synthroid - 用于甲状腺功能减退症 Lupron - 用于治疗前列腺癌、子宫内膜异位症、中枢性性早熟的以及、贫血患者术前治疗(抗癌药) Duopa和Duodopa - 左旋多巴-卡比多巴肠(levodopa-carbidopa)凝胶治疗帕金森氏病 Sevoflurane(七氟醚) - 人用麻醉药 ORILISSA - 一种非肽小分子促性腺激素释放激素拮抗剂,适用于中度至重度子宫内膜异位症疼痛的女性 TriCor, Trilipix, Niaspan, Simcor和Advicor - 用于治疗高胆固醇和/或高甘油三酯引起的代谢类疾病 Zemplar - 治疗继发性甲状旁腺功能亢进艾伯维公司AbbVie销售其产品给批发商、分销商、政府机构、医疗机构、药店和专业&独立零售商,公司目前已经与Alector, Inc.,; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company 和Calico Life Sciences LLC.达成战略合作协议。艾伯维公司AbbVie(ABBV)历史百科: 2011年10月19日, Abbott Laboratories宣布计划分成两家上市公司,新的Abbott Laboratories将专注于从事医疗器械,诊断设备和营养产品等多元化产品,而AbbVie作为一家以研究为基础的制药企业运营。分拆于2013年1月1日正式生效,AbbVie从次日开始在纽交所交易。 2014年1月,AbbVie公司收购了ImmuVen。 2014年9月3日,AbbVie和Infinity Pharmaceuticals宣布,他们已经进入全球合作,开发和商业化Duvelisib,Infinity的PI3K抑制剂治疗癌症产品。在同一天,AbbVie和Calico(California Life Company,谷歌旗下公司)宣布,他们已经进行了研发合作,旨在发现,开发和推出具有年龄相关疾病(包括神经退行性疾病和癌症)的患者的新疗法。 2014年10月,经过长时间的谈判,Abbvie停止了收购Shire的努力。 2015年3月4日,AbbVie宣布以210亿美金收购肿瘤公司Pharmacyclics及其治疗血液癌症产品——伊布他他(ibrutinib),阿斯利康也一直在竞标Pharmacyclics。交易于同年5月26日完成。 2015年6月3日,Abbey和Halozyme Therapeutics宣布,他们已经签署了全球合作和许可协议,将Abbvie的疗法与Halozyme的ENHANZE药物递送技术相结合,并进行开发和商业化,该协议于2016年11月终止。 截至2015年12月,AbbVie公司全球员工人数超过28,000人,为170多个国家的个人提供产品。 2016年2月10日,AbbVie与总部位于马萨诸塞州剑桥的Synlogic宣布了多年的研发合作。 2016年4月,AbbVie公司与芝加哥大学合作研究了肿瘤学领域的一些领域:乳腺癌,肺癌,前列腺癌,结直肠癌和血液癌。同月,AbbVie宣布将联合Argenx将后者的临床前免疫治疗产品ARGX-115联合商业化。该公司还宣布一项协议,共同开发/商业化至少一种CytomX Probody的缀合物与CD71(转铁蛋白受体1)。 2016年4月28日,AbbVie公司宣布将以98亿美元收购Stemcentrx。 2019年6月25日,AbbVie Inc.宣布同意以630亿美金收购竞争对手制药商Allergan Plc。

交易日期 交易人 职位 类型 交易份额 价格
2019-08-01 Gonzalez (Richard A) Chief Executive Officer Gift 15333 --
2019-07-31 Austin (Roxanne S) Director Buy 25000 65.66
2019-07-30 Austin (Roxanne S) Director Buy 30000 66.02
2019-07-29 Austin (Roxanne S) Director Buy 10000 66.35
2019-07-28 Gosebruch (Henry O) Officer Buy 30000 67.28
2019-07-24 Durkin (Brian L.) Officer Sell 613 67.46
2019-06-25 Rapp (Edward J ) Director Buy 7500 67.30
2019-06-25 Chase (William J) Officer Buy 30400 67.30
2019-06-25 Austin (Roxanne S) Director Buy 11500 67.50
2019-05-21 Gonzalez (Richard A) Chief Executive Officer Gift 6375 --
2019-05-02 Roberts (Rebecca B) Director Buy 2419 --
2019-05-02 Rapp (Edward J ) Director Buy 2419 --
2019-05-02 Tilton (Glenn Fletcher) Director Buy 2419 --
2019-05-02 Meyer (Melody B) Director Buy 2419 --
2019-05-02 Liddy (Edward M) Director Buy 2419 --
2019-05-02 Hart Brett J Director Buy 2419 --
2019-05-02 Austin (Roxanne S) Director Buy 2419 --
2019-05-02 Waddell (Frederick H) Director Buy 2419 --
2019-05-02 Burnside (William H L) Director Buy 2419 --
2019-05-02 Alpern (Robert J) Director Buy 2419 --
2019-03-24 Durkin (Brian L.) Officer Sell 475 79.69
2019-03-13 Schumacher (Laura J) Officer Sell 25000 80.00
2019-03-04 Saleki-Gerhardt (Azita Ph.D.) Officer Sell 15797 79.03
2019-02-27 Severino (Michael) Officer Sell 26710 79.41
2019-02-27 Gosebruch (Henry O) Officer Sell 22956 79.41

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Fidelity SelectCo, LLC 14601621 0.99% 4553797 45.32% 2019-07-31
Capital Research & Mgmt Co - Division 3 24658867 1.67% -4961746 -16.75% 2019-03-31
BlackRock Fund Advisors 27660214 1.87% -1911127 -6.46% 2019-07-31
Vanguard Investments Australia Ltd 41613696 2.81% -221966 -0.53% 2019-07-31
State Street Corporation 66198521 4.48% 1931978 3.01% 2019-03-31
BlackRock Inc 95194963 6.44% -593936 -0.62% 2019-03-31
Vanguard Group Inc 120844140 8.17% 260715 0.22% 2019-03-31
Capital Research and Management Company 136480689 9.23% -52597426 -27.82% 2019-07-31
Capital Research Global Investors 146508345 9.91% -27059898 -15.59% 2019-03-31
State Street Global Advisors 24400021 1.65% 12775 0.05% 2019-07-31
Geode Capital Management, LLC 21404788 1.45% -13760266 -39.13% 2019-03-31
Northern Trust Corp 20212084 1.37% -817581 -3.89% 2019-03-31
SSGA Funds Management Inc 14726089 1.00% 35721 0.24% 2019-07-31
Bank of America Corporation 14914363 1.01% -928031 -5.86% 2019-03-31
Putnam Investment Management, LLC 15043666 1.02% 2864884 23.52% 2019-07-31
Bank of New York Mellon Corp 15814899 1.07% -106534 -0.67% 2019-03-31
State Street Global Advisors (Aus) Ltd 16003132 1.08% -715302 -4.28% 2019-07-31
Capital World Investors 17729627 1.20% -1593555 -8.25% 2019-03-31
Orbis Allan Gray Ltd 17810182 1.20% 1203644 7.25% 2019-03-31
Northern Trust Investments N A 20212084 1.37% -817581 -3.89% 2019-03-31
Fidelity Management & Research Company 14231947 0.96% 3220395 29.25% 2019-07-31
FMR Inc 13200141 0.89% 4765946 56.51% 2019-03-31
Fidelity Management and Research Company 13176838 0.89% 4771327 56.76% 2019-03-31
BlackRock Japan Co Ltd 21694716 1.47% 19514 0.09% 2019-05-31
BlackRock Asset Management Canada Ltd 46154090 3.12% 45496 0.10% 2019-05-31
Wells Fargo & Co 13328880 0.90% 1272084 10.55% 2018-12-31
Morgan Stanley - Brokerage Accounts 12859826 0.87% 821082 6.82% 2018-12-31
TIAA-CREF Investment Management LLC 14381696 0.97% 6225630 76.33% 2018-09-30
Goldman Sachs Group Inc 13281688 0.88% 671132 5.32% 2018-09-30
BlackRock Institutional Trust Company NA 38572780 2.56% -5392893 -12.27% 2018-06-30
Arrowstreet Capital Limited Partnership 11980294 0.80% 3763730 45.81% 2018-06-30
State Street Corp 60801253 4.02% -2794830 -4.39% 2018-06-30
State Farm Mutual Automobile Ins Co 9775209 0.65% -- -- 2018-06-30
Morgan Stanley Smith Barney LLC 8777636 0.58% -197984 -2.21% 2018-06-30
Wells Fargo Advisors, LLC 7582240 0.50% -347320 -4.38% 2018-06-30
Allianz Global Investors Mnged Accounts 7507910 0.50% 7507910 -- 2018-06-30
Allianz Asset Management AG 7507910 0.50% -406808 -5.14% 2018-06-30
UBS Securities LLC 7244708 0.48% 527183 7.85% 2018-06-30
Mellon Capital Management Corporation 7218234 0.48% -184645 -2.49% 2018-06-30
Merrill Lynch & Co Inc 7124644 0.47% 516305 7.81% 2018-06-30
Legal & General Group PLC 7053670 0.47% -548337 -7.21% 2018-06-30
Managed Account Advisors LLC 9108586 0.57% 3886296 74.42% 2018-03-31
Columbia Management Company 6802896 0.43% -74408 -1.08% 2018-03-31
Goldman, Sachs & Co. 8040358 0.51% -935580 -10.42% 2018-03-31
Jennison Associates LLC 11353745 0.71% 5227056 85.32% 2017-12-31
NORGES BANK 13729223 0.86% -592246 -4.14% 2017-12-31
Federated Investment Management Company 10521204 0.66% -4149911 -28.29% 2017-09-30
Sunamerica Asset Management Corp 7737912 0.48% -35461 -0.46% 2017-09-30
Epoch Investment Partners Inc 7865090 0.49% -496620 -5.94% 2017-09-30
LSV Asset Management 6842773 0.43% 214187 3.23% 2017-09-30
Highfields Capital Management LP 7962839 0.49% -- -- 2016-09-30
Government Pension Fund of Norway - Global 10791970 0.68% 10791970 -- 2013-12-31
Woodford Investment Management LLP 11029800 0.68% -627000 -5.38% 2016-09-30
Baker Bros Advisors LP 14343358 0.88% -30180 -0.21% 2016-09-30
Janus Capital Management LLC 14578930 0.90% -6614933 -31.21% 2016-09-30
The Vanguard Group 88843397 1.00% 2147483647 0.10% 1999-11-30
BlackRock, Inc. 114453015 1.00% 2147483647 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Fidelity Advisor 5149276 0.35% 2059500 66.66% 2019-06-30
Vanguard Total Stock Market Index Fund 41014535 2.77% -223775 -0.54% 2019-06-30
American Funds Invmt Co of Amer 33542728 2.27% -11212965 -25.05% 2019-06-30
American Funds Capital Income Bldr 29254500 1.98% -3525100 -10.75% 2019-06-30
Vanguard 500 Index Fund 29090465 1.97% 356841 1.24% 2019-06-30
American Funds Capital World Gr&Inc Fd 19987300 1.35% -3590916 -15.23% 2019-06-30
Vanguard Institutional Index Fund 13803258 0.93% -74168 -0.53% 2019-06-30
American Funds American Mutual Fund 13454899 0.91% -2704201 -16.73% 2019-06-30
American Funds AMCAP Fund 11485959 0.78% -6691367 -36.81% 2019-06-30
American Funds Growth Fund of Amer 11065779 0.75% -6673900 -37.62% 2019-06-30
iShares Core S&P 500 ETF 10847347 0.73% -5346 -0.05% 2019-07-30
SPDR 5173951 0.35% -- -- 2019-07-31
Vanguard Growth Index Fund 5283763 0.36% -5109198 -49.16% 2019-06-30
Federated Strategic Value Dividend Fund 5455500 0.37% -- -- 2019-06-30
American Funds IS 6028530 0.41% 34330 0.57% 2019-06-30
State Street S&P 500 Index Fund 6384507 0.43% 4400 0.07% 2019-06-30
Health Care Select Sector SPDR 7438002 0.50% 13832 0.19% 2019-07-31
Fidelity 8390217 0.57% 2000000 31.30% 2019-06-30
American Funds Washington Mutual Fund 7432650 0.50% -3151500 -29.78% 2019-03-31
iShares Core MSCI Kokusai ETF 10847358 0.73% 9757 0.09% 2019-05-30
iShares Core S&P 500 ETF (CAD-Hedged) 10847358 0.73% 9757 0.09% 2019-05-30
iShares S&P 500 ETF 10847358 0.73% 9757 0.09% 2019-05-30
iShares Core S&P US Total Market ETF 10847358 0.73% 9757 0.09% 2019-05-30
iShares MSCI World ETF 10805669 0.73% 3548 0.03% 2019-05-23
iShares Core MSCI AllCntry Wld exCan ETF 10805669 0.73% 3548 0.03% 2019-05-23
Vanguard High Dividend Yield Index Fund 4732510 0.32% 56335 1.20% 2019-03-31
iShares Russell 1000 Growth ETF 4843953 0.33% -- -- 2019-03-29
VA CollegeAmerica Capital Inc Builder 33333800 2.26% -95200 -0.28% 2018-12-31
VA CollegeAmerica The Gr Fd of Amer 31297441 2.12% -157515 -0.50% 2018-12-31
VA CollegeAmerica Capital Wld Gr & Inc 23032266 1.56% -5970807 -20.59% 2018-12-31
VA CollegeAmerica AMCAP Fd 20419227 1.38% -- -- 2018-12-31
VA CollegeAmerica Amer Mutl Fd 16355600 1.11% 66800 0.41% 2018-12-31
VA CollegeAmerica WA Mutl Inv Fd 10584150 0.72% 809600 8.28% 2018-12-31
VA CollegeAmerica The Inv Co of Amer 56947449 3.86% -933000 -1.61% 2018-12-31
AIG Focused Dividend Strategy Fund 4328200 0.29% -248203 -5.42% 2018-12-31
OH Putnam Fidelity Spartan 500 Index 11268916 0.76% 326059 2.98% 2019-01-31
BlackRock Russell 1000 Index Fund 4158302 0.28% 81848 2.01% 2018-12-31
Undrly L&G Diversified Life 6582698 0.44% 6550704 20474.79% 2018-09-30
Undrly L&G Pen PMC Diversified 6582698 0.44% 6550704 20474.79% 2018-09-30
VA CollegeAmerica Amcap 529F 18121000 1.20% -- -- 2018-06-30
VA CollegeAmerica Grth Fund of Amer 529F 23553441 1.56% 1016971 4.51% 2018-06-30
Vanguard 500 Index Inv 27443605 1.81% 28988 0.11% 2018-07-31
VA CollegeAmerica Cap World G/I 529E 29611073 1.96% 300000 1.02% 2018-06-30
VA CollegeAmerica Cap Inc Bldr 529E 30893000 2.04% -- -- 2018-06-30
Vanguard Total Stock Mkt Idx 38089751 2.52% 155184 0.41% 2018-07-31
VA CollegeAmerica Invmt Co of Amer 529E 57880449 3.82% -- -- 2018-06-30
VA CollegeAmerica Amercn Mutual 529E 16465700 1.09% -- -- 2018-06-30
Vanguard Institutional Index I 14661598 0.97% 17072 0.12% 2018-07-31
Vanguard Growth Index Inv 10672865 0.70% -30989 -0.29% 2018-07-31
CREF Stock R1 3872464 0.26% -253426 -6.14% 2018-07-31
Vanguard High Dividend Yield ETF 4626758 0.31% 6604 0.14% 2018-07-31
SunAmerica Focused Dividend Strategy A 4666759 0.31% -50925 -1.08% 2018-07-31
iShares Russell 1000 Growth 5176304 0.33% -3560 -0.07% 2018-09-12
American Funds NVIT Growth-Income II 6563841 0.43% -685000 -9.45% 2018-06-30
Fidelity Spartan 10094903 0.67% 119070 1.19% 2018-07-31
VA CollegeAmerica WA Mutual 529B 10256922 0.68% -792528 -7.17% 2018-06-30
VA CollegeAmerica Amercn Bal 529E 5045000 0.32% 145000 2.96% 2018-03-31
Federated Strategic Value Dividend A 6860400 0.43% -3086750 -31.03% 2017-09-30
SPDR® S&P 500® ETF Trust 15912798 1.00% -- -- 2015-09-30
SPDR® S&P 500 ETF 16062202 1.00% 121002 0.80% 2015-11-19
VA CollegeAmerica American Mutual 17775000 1.10% -- -- 2015-09-30
VA CollegeAmerica Invmt Co of America 21561000 1.30% -4403000 -17.00% 2015-09-30
VA CollegeAmerica Cap World Gr and Inc 10730829 0.70% -579714 -5.10% 2015-09-30
Health Care Select Sector SPDR® Fund 8400329 0.50% -37600 -0.40% 2015-11-19
Fidelity Spartan® 500 Index Fd 8144125 0.50% -298870 -3.50% 2015-09-30
Fidelity® Select Health Care Portfolio 7400000 0.40% 500000 7.20% 2015-09-30
CREF Stock Account 6849562 0.40% -106284 -1.50% 2015-09-30
M&G Global Dividend 6340964 0.40% -238060 -3.60% 2015-07-31
VA CollegeAmerica Cap Income Builder 29543801 1.80% -1895000 -6.00% 2015-09-30

Roxanne Schuh Austin Currently, Roxanne Schuh Austin is President & Chief Executive Officer at Austin Investment Advisors. Ms. Austin is also Member of California Society of Certified Public Accountants and Member of The American Institute of Certified Public Accountants and on the board of 6 other companies. In the past Ms. Austin held the position of President, Chief Executive Officer & Director at Move Networks, Inc., President & Chief Operating Officer of DIRECTV, Chief Financial Officer & Executive Vice President for The DIRECTV Group, Inc. and Partner at Deloitte & Touche LLP. Roxanne Schuh Austin received an undergraduate degree from The University of Texas.
Edward J. Rapp Edward J. Rapp is Member-Business Strategic Development Board at the University of Missouri and on the board of 5 other companies. In his past career he was Group President-Resource Industries at Caterpillar, Inc. and Chief Executive Officer for Caterpillar (U.K.) Ltd. (a subsidiary of Caterpillar, Inc.). Mr. Rapp received an undergraduate degree from the University of Missouri.
Frederick H. Waddell Currently, Frederick H. Waddell is Chairman, President & Chief Executive Officer at Northern Trust Securities, Inc. Mr. Waddell is also on the board of 15 other companies. In his past career Mr. Waddell held the position of Chairman for Northern Trust Corp. Chairman & Chief Executive Officer of Northern Trust Investments, Inc.(Investment Management) and Chairman & Chief Executive Officer of The Northern Trust Co. (both are subsidiaries of Northern Trust Corp.). He received an undergraduate degree from Dartmouth College and an MBA from Kellogg School of Management.
Laura J. Schumacher Laura J. Schumacher is Chief Legal Officer at AbbVie, Inc. She is also on the board of General Dynamics Corp., Ronald McDonald House Charities, Inc., Clara Abbott Foundation and Ronald Mcdonald House Charities and Member of The Chicago Network, Member of The Economic Club of Chicago and Member of The Chicago Club. In the past she occupied the position of Associate Attorney at Schiff Hardin LLP, Senior VP, Director-Risk Management & Audit at FB Corp. (Missouri) and Secretary, Executive VP & General Counsel for Abbott Laboratories. She received an undergraduate degree from the University of Notre Dame and a graduate degree from the University of Wisconsin.
Rebecca Brown Roberts Rebecca Brown Roberts is on the board of Mine Safety Appliances Co. LLC and 4 other companies. Ms. Roberts previously held the position of President of Chevron Global Power Co. and President at Chevron Pipe Line Co. She received an undergraduate degree from McNeese State University.
Carlos Alban Carlos Alban is on the board of Pharmaceutical Research & Manufacturers of America and Vice Chairman & Chief Commercial Officer at AbbVie, Inc. Mr. Alban previously held the position of Senior VP-Proprietary Pharmaceutical Products at Abbott Laboratories Vice President-Pharmaceuticals at Abbott Canada, Product Manager at Abbott Laboratories de Colombia SA and General Manager for Abbott Laborat�0�1�0�6rios Lda. (which are all subsidiaries of Abbott Laboratories). He received a graduate degree from Universidad de Los Andes and an undergraduate degree from Pontificia Universidad Javeriana.
Glenn Fletcher Tilton Glenn Fletcher Tilton is a businessperson who has been at the head of 11 different companies is Chairman for The Chicago Council on Global Affairs and Director-Ambassadors Discovery Ball at American Cancer Society, Inc. and on the board of 10 other companies. In the past he held the position of Non-Executive Chairman for United Airlines Holdings, Inc. Chairman, President & Chief Executive Officer at UAL Corp. and Non-Executive Chairman & Chief Executive Officer at United Air Lines, Inc. (both are subsidiaries of United Airlines Holdings, Inc.), Chairman, President & Chief Executive Officer at City of Elk Grove (Illinois), Chairman for Airlines for America, Inc., Chairman-Midwest Business at JPMorgan Chase & Co., Chairman & Chief Executive Officer for Texaco, Inc., Non-Executive Chairman of Dynegy, Inc., Vice Chairman at Chevron Texaco Corp., President at Texaco Canada, Inc. and President at Valero Energy UK Ltd. Glenn Fletcher Tilton received an undergraduate degree from the University of South Carolina.
Richard A. Gonzalez Presently, Richard A. Gonzalez is Chairman & Chief Executive Officer for AbbVie, Inc. In the past he held the position of President & Chief Operating Officer for Abbott Laboratories President at Abbott Ventures, Inc. and Divisional Vice President & General Manager at Abbott Diagnostics, Inc. (both are subsidiaries of Abbott Laboratories), Chief Executive Officer-Operations at Abbott Laboratories President at Abbott Ventures, Inc. and Divisional Vice President & General Manager at Abbott Diagnostics, Inc. (both are subsidiaries of Abbott Laboratories), President & Senior Vice President at Hospira, Inc. and Executive Vice President of Pharmaceutical Products. Richard A. Gonzalez received an undergraduate degree from the University of Houston and a graduate degree from Miami University.
Edward Michael Liddy Edward Michael Liddy is a businessperson who has been the head of 6 different companies is on the board of Abbott Laboratories and 7 other companies. In the past Mr. Liddy was Chairman & Chief Executive Officer at American International Group, Inc., Chairman for The Allstate Corp. and Chairman of Allstate Life Insurance Co. (a subsidiary of The Allstate Corp.), Chairman for US Foods, Inc., Chairman of The ServiceMaster Co. LLC, Chief Financial Officer at Sears, Roebuck & Co., Partner at Clayton Dubilier & Rice LLC, Secretary of US Department of The Treasury and Chairman at Northwestern Memorial HealthCare. He received an undergraduate degree from The Catholic University of America and an MBA from George Washington University.
William H. L. Burnside William H. L. Burnside is on the board of AbbVie, Inc., Executive Service Corps of Southern California and Audubon California, Inc. He previously occupied the position of Director & Senior Vice President at The Boston Consulting Group, Inc. He received an undergraduate degree from Jesus College Cambridge and an MBA from Harvard Business School.
Ronald O. Robison Ronald O. Robison is Member of Radiological Society of North America, Inc. and Vice President-Regulatory Affairs of AbbVie, Inc. He previously occupied the position of Head-Global Regulatory Affairs & Vice President at Abbott Laboratories and Chief Medical Officer, SVP-Research & Development at Solvay Pharmaceuticals, Inc. (a subsidiary of Abbott Laboratories), Medical Director-Worldwide & Senior Vice President at Amersham Health, Chief Medical Officer & VP-Clinical Research at Fougera Pharmaceuticals, Inc., Associate Director-Clinical Research at Mallinckrodt Medical, Inc. and Research Assistant at Oregon Health Sciences University. Ronald O. Robison received an undergraduate degree from Oregon State University, a graduate degree from the University of Utah and a doctorate from Oregon Health Sciences University.
David Laskow-Pooley David Laskow-Pooley founded Pharmafor Ltd. Presently, he is Chairman of NeuroVive Pharmaceutical AB. He is also Vice President-Product Development at Q BioMed, Inc. and on the board of 7 other companies. In his past career he was Chairman of OBN (UK) Ltd., Chief Executive Officer & Director at LondonPharma Ltd., Chief Executive Officer for Surface Therapeutics Ltd. and Managing Director-UK Division at OSI Pharmaceuticals, Inc. He received an undergraduate degree from the University of Sunderland.
Brett J. Hart Currently, Brett J. Hart is Chief Administrative Officer & General Counsel at United Airlines Holdings, Inc. and Chief Administrative Officer & EVP at United Airlines, Inc. (a subsidiary of United Airlines Holdings, Inc.). He is also on the board of AbbVie, Inc., The Chicago Council on Global Affairs and The Chicago Urban League. In the past he occupied the position of Partner at Sonnenschein Nath & Rosenthal LLP, Secretary, Senior Vice President & General Counsel at UAL Corp., Secretary, EVP & General Counsel at The Hillshire Brands Co. and Secretary, Executive VP & General Counsel of Continental Airlines, Inc. Mr. Hart received an undergraduate degree from the University of Michigan and a graduate degree from The University of Chicago Law School.
Robert J. Alpern Robert J. Alpern holds the position of President of Austin Investment Advisors. He is also on the board of Abbott Laboratories, AbbVie, Inc., Tricida, Inc. and Yale-New Haven Hospital, Inc. and Professor at Yale School of Medicine and Professor at Medicine Hat College. In his past career he occupied the position of Dean at The University of Texas Southwestern Medical Center.
William Joseph Chase Currently, William Joseph Chase is Executive Vice President-Finance & Administration at AbbVie, Inc. Mr. Chase is also on the board of Junior Achievement of Chicago, AbbVie Investments Ltd., AbbVie Ltd. (United Kingdom) and AbbVie Australasia Holdings Ltd. He previously held the position of Vice President-Licensing & Acquisitions at Abbott Laboratories and Divisional Vice President & Controller at Abbott International LLC (a subsidiary of Abbott Laboratories).
Azita Saleki-Gerhardt Presently, Azita Saleki-Gerhardt occupies the position of Executive Vice President-Operations for AbbVie, Inc. She is also on the board of Entegris, Inc. In the past she held the position of President-Global Pharmaceutical Operations at Abbott Laboratories. She received an undergraduate degree, a graduate degree and a doctorate from the University of Wisconsin.
Melody B. Meyer Currently, Melody B. Meyer occupies the position of President of Melody Meyer Energy LLC. Ms. Meyer is also on the board of 5 other companies. In her past career she occupied the position of VP-Gulf of Mexico Business Unit at Chevron Oil Co., President for Chevron Energy Technology Co. and President-Asia Pacific Exploration at Chevron Singapore Pte Ltd. Ms. Meyer received an undergraduate degree from Trinity University.
Michael E. Severino Michael E. Severino occupies the position of Vice Chairman & President at AbbVie, Inc. He is also on the board of Biotechnology Innovation Organization. He previously was Chief Medical Officer & SVP-Global Development at Amgen, Inc. and Senior Vice President at Amgen Ventures LLC (a subsidiary of Amgen, Inc.). Dr. Severino received a doctorate from The Johns Hopkins University.
Timothy J. Richmond Currently, Timothy J. Richmond is Chief Human Resources Officer & Executive VP for AbbVie, Inc. In the past Mr. Richmond was Vice President-Compensation & Benefits Division at Abbott Laboratories, Vice President of Talent Acquisitions LLC and Divisional Vice President at C.A.P.S., Inc.
Liz Shea Presently, Liz Shea holds the position of Head-Investor Relations of AbbVie, Inc.
Karen Hale Presently, Karen Hale is VP, Chief Compliance & Ethics Officer at AbbVie, Inc.
Henry O. Gosebruch Henry O. Gosebruch is on the board of Aptinyx, Inc. and Chief Strategy Officer & Executive Vice President at AbbVie, Inc. Mr. Gosebruch previously held the position of Co-Head-Mergers & Acquisitions North America at JPMorgan Securities LLC. Mr. Gosebruch received an undergraduate degree from The Wharton School of the University of Pennsylvania.
Esteban Plata Esteban Plata is Vice President-Western Europe & Canada at AbbVie, Inc.
Robert A. Michael Robert A. Michael occupies the position of Chief Financial Officer & Senior Vice President for AbbVie, Inc. Mr. Michael previously was Division Controller-Nutrition Supply Chain at Abbott Laboratories.
Scott Brun Scott Brun is Vice President & Head-AbbVie Ventures at AbbVie, Inc. and Head-Clinical Development at Abbott Laboratories.
Sharon Curran Sharon Curran is on the board of Circassia Pharmaceuticals Plc and Vice President-Global Specialty Franchise at AbbVie, Inc. She received a graduate degree from Trinity College Dublin and an undergraduate degree from Dublin City University.
Brian L. Durkin Brian L. Durkin is Principal Accounting Officer, VP & Controller at AbbVie, Inc. He previously occupied the position of VP-Finance & Controller-Abbotts Vision Care at Abbott Laboratories.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐